Anti-Metastatic Cell Cluster Therapy

About TumorGen

TumorGen is a private, pre-clinical stage biotech targeting the root cause of cancer mortality: metastasis. The company is developing a proprietary drug discovery platform to identify compounds that disassociate metastatic cell clusters (MCCs), thereby stopping cancer spread. Led by a founder with a personal mission and a team combining scientific and financial expertise, TumorGen is positioning itself in a high-need, high-value oncology segment. Its business model is therapeutic, and it is currently pre-revenue, seeking investment and collaborations to advance its pipeline.

Therapeutic Areas